Peregrine Capital Management LLC Purchases 15,070 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Peregrine Capital Management LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 28.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,874 shares of the biotechnology company's stock after purchasing an additional 15,070 shares during the quarter. Peregrine Capital Management LLC owned about 0.07% of Sarepta Therapeutics worth $4,396,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SRPT. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $3,829,000. Smartleaf Asset Management LLC boosted its stake in Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after buying an additional 216 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Sarepta Therapeutics by 274.5% during the fourth quarter. Jones Financial Companies Lllp now owns 528 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 387 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 194 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after acquiring an additional 12,000 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Analysts Set New Price Targets

SRPT has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating for the company in a report on Tuesday, June 17th. Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $125.00 to $50.00 and set a "buy" rating for the company in a report on Monday, June 16th. TD Cowen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price target for the company. in a research report on Wednesday, June 18th. JPMorgan Chase & Co. lowered their price objective on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 20th. Finally, William Blair reissued a "market perform" rating on shares of Sarepta Therapeutics in a research note on Friday, June 20th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Hold" and an average price target of $60.88.

Sarepta Therapeutics Price Performance

Shares of SRPT traded up $0.03 during mid-day trading on Thursday, reaching $18.22. The company had a trading volume of 2,484,387 shares, compared to its average volume of 2,188,251. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The company has a market capitalization of $1.79 billion, a P/E ratio of -6.77 and a beta of 0.45. Sarepta Therapeutics, Inc. has a twelve month low of $16.88 and a twelve month high of $154.90. The company's 50-day moving average is $36.19 and its 200-day moving average is $76.16.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. Sarepta Therapeutics's quarterly revenue was up 80.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 EPS. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.